Article
Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors.
Science (New York, N.Y.) - 8 Nov 2019
Vasan Neil, Razavi Pedram, Johnson Jared L, Shao Hong, Shah Hardik, Antoine Alesia, Ladewig Erik, Gorelick Alexander, Lin Ting-Yu, Toska Eneda, Xu Guotai, Kazmi Abiha, Chang Matthew T, Taylor Barry S, Dickler Maura N, Jhaveri Komal, Chandarlapaty Sarat, Rabadan Raul, Reznik Ed, Smith Melissa L, Sebra Robert, Schimmoller Frauke, Wilson Timothy R, Friedman Lori S, Cantley Lewis C, Scaltriti Maurizio, Baselga José
Abstract excerpt
Activating mutations in PIK3CA are frequent in human breast cancer, and phosphoinositide 3-kinase alpha (PI3Kα) inhibitors have been approved for therapy. To characterize determinants of sensitivity to these agents, we analyzed PIK3CA-mutant cancer genomes and observed the presence of multiple PIK3CA mutations in 12 to 15% of breast cancers and other tumor types, most of which (95%) are double mutations. Double...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.